000126915 001__ 126915
000126915 005__ 20240705134147.0
000126915 0247_ $$2doi$$a10.1016/j.psychres.2023.115249
000126915 0248_ $$2sideral$$a134341
000126915 037__ $$aART-2023-134341
000126915 041__ $$aeng
000126915 100__ $$aSegura, A. G
000126915 245__ $$aExploration of cannabis use and polygenic risk scores on the psychotic symptom progression of a FEP cohort
000126915 260__ $$c2023
000126915 5060_ $$aAccess copy available to the general public$$fUnrestricted
000126915 5203_ $$aCannabis use is highly prevalent in first-episode psychosis (FEP) and plays a critical role in its onset and prognosis, but the genetic underpinnings promoting both conditions are poorly understood. Current treatment strategies for cannabis cessation in FEP are clearly inefficacious. Here, we aimed to characterize the association between cannabis-related polygenic risk scores (PRS) on cannabis use and clinical course after a FEP. A cohort of 249 FEP individuals were evaluated during 12 months. Symptom severity was measured with the Positive and Negative Severity Scale and cannabis use with the EuropASI scale. Individual PRS for lifetime cannabis initiation (PRSCI) and cannabis use disorder (PRSCUD) were constructed. Current cannabis use was associated with increased positive symptoms. Cannabis initiation at younger ages conditioned the 12-month symptom progression. FEP patients with higher cannabis PRSCUD reported increased baseline cannabis use. PRSCI was associated with the course of negative and general symptomatology over follow-up. Cannabis use and symptom progression after a FEP were modulated by cannabis PRS, suggesting that lifetime initiation and use disorders may have partially independent genetic factors. These exploratory results may be the first step to identify those FEP patients more vulnerable to cannabis use and worse outcomes to ultimately develop tailored treatments.
000126915 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/CD20-00177$$9info:eu-repo/grantAgreement/ES/ISCIII/PI08-0208$$9info:eu-repo/grantAgreement/ES/ISCIII/PI20-00661$$9info:eu-repo/grantAgreement/ES/MINECO/PI11-00325$$9info:eu-repo/grantAgreement/ES/MINECO/PI14-00612
000126915 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000126915 592__ $$a2.189$$b2023
000126915 593__ $$aPsychiatry and Mental Health$$c2023$$dQ1
000126915 593__ $$aBiological Psychiatry$$c2023$$dQ1
000126915 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000126915 700__ $$aMané, A.
000126915 700__ $$aProhens, Ll.
000126915 700__ $$aRodríguez, N.
000126915 700__ $$aMezquida, G.
000126915 700__ $$aCuesta, M. J
000126915 700__ $$aVieta, E.
000126915 700__ $$aAmoretti, S.
000126915 700__ $$0(orcid)0000-0002-9098-655X$$aLobo, A.$$uUniversidad de Zaragoza
000126915 700__ $$aGonzález-Pinto, A.
000126915 700__ $$aDíaz-Caneja, C. M.
000126915 700__ $$aRoldán Bejarano, A.
000126915 700__ $$aJiménez, E.
000126915 700__ $$aBaeza, I.
000126915 700__ $$aLegido, T.
000126915 700__ $$aSaiz-Ruiz, J.
000126915 700__ $$aBernardo, M.
000126915 700__ $$aMas, S.
000126915 700__ $$aPEPs Group
000126915 7102_ $$11007$$2745$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Psiquiatría
000126915 773__ $$g325 (2023), 115249 [7 pp.]$$pPsychiatry res.$$tPSYCHIATRY RESEARCH$$x0165-1781
000126915 8564_ $$s487860$$uhttps://zaguan.unizar.es/record/126915/files/texto_completo.pdf$$yVersión publicada
000126915 8564_ $$s2268172$$uhttps://zaguan.unizar.es/record/126915/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000126915 909CO $$ooai:zaguan.unizar.es:126915$$particulos$$pdriver
000126915 951__ $$a2024-07-05-12:47:44
000126915 980__ $$aARTICLE